Skip to content
Frontiers
Search

Review

Frontiers in Clinical Diabetes and Healthcare ·

Volume 7 - 2026 | https://doi.org/10.3389/fcdhc.2026.1823872

Pathogenesis of diabetic cardiomyopathy and emerging therapeutic strategies: a network-based perspective

  • Haoqing Ren1,2
  • Hengli Lai2*corresponding author
  1. 1Jiangxi Medical College, Nanchang University, Nanchang, China
  2. 2Department of Cardiology, Jiangxi Provincial People’s Hospital, The First Affiliated Hospital of Nanchang Medical College, Nanchang, China
Article metrics0 viewsView details
PDFCiteMetrics

Abstract

Diabetic cardiomyopathy (DCM) is a distinct myocardial disease in diabetic patients, independent of coronary artery disease or hypertension, and a leading cause of heart failure. Its pathogenesis has evolved from a linear “glucolipotoxicity” model to a complex, dynamic network involving metabolic disturbances, mitochondrial dysfunction, oxidative stress, chronic inflammation, diverse programmed cell death pathways, cellular senescence, and cardiac autonomic neuropathy. These interconnected events are amplified through positive feedback loops, driving progressive myocardial damage. This review provides a systems-level synthesis of the networked pathogenesis of DCM, integrating evidence across core mechanistic components and their dynamic interactions. We discuss how metabolic disturbances initiate and propagate injury signals through mitochondrial dysfunction, inflammatory activation, and alterations in cardiomyocyte fate—including apoptosis, necroptosis, ferroptosis, and senescence. Distinct from prior reviews, this article explores two emerging integrative concepts: “metabolic–structural coupling”—abnormal physical interactions between metabolic molecules and myocardial structural proteins—and “metabolic memory”—epigenetically mediated persistence of injury despite glycemic control. We further provide a horizontal comparison and stage-specific assessment of emerging therapeutic strategies, including the pleiotropic network effects of SGLT2 inhibitors, the cardiovascular benefits of GLP-1 receptor agonists, targeting ferroptosis (e.g. irisin, alpha-lipoic acid), senolytics (e.g. dasatinib + quercetin), and the modulation of lipid droplet dynamics and the farnesoid X receptor (FXR). Finally, we critically evaluate the current evidence levels and translational barriers for these emerging therapies—from preclinical targets to completed randomized controlled trials—and propose a forward-looking roadmap to advance precision medicine in DCM. This roadmap emphasizes the multi-omics dissection of clinical heterogeneity, the development of mechanism-based biomarkers, and the validation of targeted combination therapies in well-designed clinical trials, with metabolic-structural coupling and metabolic memory serving as integrative links between classical pathways and disease persistence.

Keywords

1 Introduction

Cardiovascular complications of diabetes have become a major global public health challenge. Beyond accelerating atherosclerosis, diabetes can directly damage the myocardium, leading to a specific cardiomyopathy—diabetic cardiomyopathy (DCM) (1). DCM is characterized by progressive structural and functional cardiac abnormalities in the absence of significant coronary artery disease, hypertension, or valvular heart disease. Its clinical course typically begins with subclinical diastolic dysfunction and may eventually progress to symptomatic heart failure, regardless of ejection fraction (2, 3), “Pure” DCM (excluding hypertension and CAD) occurs in 3%-17% of diabetic patients, depending on diagnostic criteria. However, up to 64% have some cardiac abnormality when comorbidities are included.

For decades, the “glucolipotoxicity” model dominated the pathophysiological understanding of DCM, emphasizing direct myocardial injury caused by high glucose and free fatty acids (4, 5). Although instructive, this relatively linear framework fails to fully explain the complexity of DCM phenotypes, particularly the phenomenon where cardiac injury continues to progress even after strict glycemic control in advanced stages (6). This limitation has prompted a profound shift in perspective. Recently, research has moved from isolated “toxic pathways” toward understanding a highly interconnected, dynamically interacting molecular network. This network is initiated by metabolic disturbances and subsequently triggers mitochondrial dysfunction, redox imbalance, chronic low-grade inflammation, multiple forms of programmed cell death, epigenetic reprogramming, and abnormal intercellular communication—events that are not linearly transmitted but intertwined, forming complex feedback loops (3, 7–9).

Compared with previous reviews, the novel contributions of this article are: (1) it systematically integrates the emerging concepts of “metabolic–structural coupling” and “metabolic memory” into a unified network framework, elucidating their interactions with classical pathways; (2) it provides a horizontal comparison and stage-specific assessment of emerging therapeutic targets, clarifying their evidence levels and developmental stages; (3) it reinterprets the mechanisms of pleiotropic drugs such as SGLT2 inhibitors from a network biology perspective. This review aims to systematically construct a network-based framework of DCM pathogenesis and, on this basis, provide a comprehensive overview of emerging therapeutic strategies.

2 Core network components of DCM pathogenesis

2.1 Metabolic disturbances: the initiator and driver of the network

Below briefly synthesize these well-established pathways; detailed mechanistic descriptions are available in recent comprehensive reviews. The heart possesses remarkable metabolic flexibility, efficiently switching between fatty acid oxidation and glucose oxidation to meet energy demands (10, 11), Diabetes disrupts this balance, inducing “pathological metabolic remodeling”, which serves as the initial driver of the entire injury network.

In terms of glucose metabolism, myocardial insulin resistance leads to reduced membrane translocation of glucose transporter 4 (GLUT4) and impaired glucose uptake (3, 12, 13) GLUT4 is the main insulin-responsive glucose transporter in cardiac cells. The knockout of the cardiac-specific GLUT4 gene leads to the loss of insulin-induced glucose uptake function, confirming its crucial role in the pathogenesis of dilated cardiomyopathy. Persistent hyperglycemia mediates damage through four parallel pathways, AGE-RAGE signaling (activating NF-κB-driven inflammation), PKC activation (impairing vascular and metabolic regulation), polyol pathway flux (depleting antioxidant capacity), and hexosamine pathway flux (causing O-GlcNAc modification of key proteins) (14–19).

Lipid metabolism abnormalities and lipotoxicity also play critical roles. The heart exhibits increased uptake and β-oxidation of free fatty acids (FFAs), while glucose oxidation is suppressed. When FFA supply exceeds mitochondrial oxidative capacity, toxic lipid intermediates such as ceramides and diacylglycerols (DAG) accumulate. Ceramides are potent inducers of apoptosis, promoting insulin resistance, oxidative stress, and mitochondrial dysfunction (20). DAG can persistently activate PKC, further impairing insulin signaling and forming a vicious cycle (21, 22). Together, these abnormalities lead to a “metabolic rigidity” that reduces ATP production efficiency and causes energy deficiency, forming the energetic basis for early diastolic dysfunction in DCM. The important point is that these metabolic disorders do not completely disappear even after blood sugar levels return to normal. That is, although blood sugar is under control, through “metabolic memory”, epigenetic modifications will still continue to cause functional disorders.

2.2 Mitochondrial dysfunction and oxidative stress: energy crisis and damage amplifier

Mitochondria are central organelles where metabolic disturbances converge and amplify downstream damage signals. Lipotoxicity, hyperglycemia, and AGEs directly damage mitochondria, manifested by reduced membrane potential, impaired electron transport chain complex activity, decreased oxidative phosphorylation coupling efficiency, and reduced ATP synthesis (23, 24). Through the “metabolic memory” mechanism, the epigenetic modifications caused by high blood sugar persist even after blood sugar levels return to normal, leading to persistent mitochondrial dysfunction. In contrast, the “metabolic-structural coupling” phenomenon may extend to the mitochondrial level: metabolic molecules can physically interact with mitochondrial structural proteins, directly altering the dynamic characteristics of the mitochondria, going beyond the traditional signaling pathways. Mitochondrial dynamics are disrupted, with decreased fusion proteins (e.g. Mfn1/2) and increased fission protein Drp1, leading to excessive mitochondrial fragmentation (25–28).

Beyond mitochondria-derived ROS due to metabolic overload, hyperglycemia also activates the NADPH oxidase (NOX) family in the myocardium, contributing significantly to non-mitochondrial ROS production (29–31) Meanwhile, endogenous antioxidant defense systems are often downregulated or exhausted in diabetes. Mitophagy, the key mechanism for clearing damaged mitochondria (e.g. the PINK1/Parkin pathway), is frequently dysfunctional in DCM, leading to accumulation of defective mitochondria and further ROS generation—a self-perpetuating vicious cycle (32–36) Apart from energy failure, mitochondrial dysfunction may also contribute to “metabolic-structural coupling” by releasing metabolites that physically interact with myofilament proteins, thereby directly impairing the contractile ability.

2.3 Chronic low-grade inflammation and immune activation

Metabolic and oxidative stress jointly initiate a persistent, low-grade inflammatory state in the heart, serving as a critical bridge linking metabolic abnormalities to structural remodeling. Damage-associated molecular patterns (DAMPs) such as ROS and AGEs activate NF-κB, and the NLRP3 inflammasome, driving pro-inflammatory cytokine production (37–44).

Concomitantly, circulating monocytes are recruited to the diabetic heart and polarize toward a pro-inflammatory M1 phenotype, while reparative M2 macrophages are relatively reduced (45–49) These activated immune cells secrete large amounts of cytokines and growth factors (e.g. TGF-β), directly stimulating resident cardiac fibroblasts to transdifferentiate into matrix-producing myofibroblasts (50–53) Inflammatory signals themselves can worsen local metabolic disturbances; for example, TNF-α exacerbates myocardial insulin resistance, creating a positive feedback loop of “metabolic disturbance–inflammation–worsened metabolism”. (54, 55), This inflammatory network extends beyond the heart through interactions between organs. The adipose tissue releases adipokines that can directly regulate the inflammatory and fibrotic processes of the heart; while the liver produces hepatic factors that may exacerbate insulin resistance in the myocardium. Therefore, DCM is part of the systemic inflammatory network that connects the heart, fat, and liver.

2.4 Cardiomyocyte fate alterations: death, senescence, and dysfunction

Under persistent stress, cardiomyocytes undergo various fate changes. Programmed cell death in DCM includes apoptosis, necroptosis, pyroptosis, and ferroptosis—each with distinct molecular machinery and inflammatory consequences (56–63).

Cellular senescence is also involved: metabolic stress accelerates the entry of cardiomyocytes and cardiac stem cells into a senescent state, characterized by the senescence-associated secretory phenotype (SASP) (64–66) SASP further deteriorates the local microenvironment, promoting fibrosis and dysfunction (67, 68). At the functional level, these stresses directly impair sarcoplasmic reticulum function, reducing activity of SERCA2a and disrupting calcium handling—the most direct cellular physiological basis for contractile dysfunction (69, 70). This complex interaction can be understood as a multi-level network (Figure 1). The progression of the disease begins with metabolic bypasses driven by glycolipid toxicity, such as the polyol pathway and the formation of AGEs, and then is exacerbated through a bidirectional interaction between mitochondrial oxidative stress and inflammation. Eventually, these interrelated disorders ultimately lead to irreversible structural remodeling and the occurrence of multiple cell death programs, including ferroptosis and senescence, which are mediated by key molecular coupling mechanisms. Unlike a linear cascade, this network has reinforcing relationships between all levels, without a single “starting point” or “endpoint”. The schematic emphasizes that DCM pathogenesis represents not linear toxicity from individual pathways, but rather a dynamic, self-amplifying network of molecular and cellular events wherein metabolic disturbances, structural disruption, inflammatory signaling, and epigenetic memory continuously reinforce one another to drive disease progression.

The interconnected pathophysiological network of diabetic cardiomyopathy (DCM). This schematic delineates a non-linear network where metabolic disturbances (glucolipotoxicity and AGEs) and cellular stressors (mitochondrial dysfunction, inflammation, and impaired calcium handling) form mutually reinforcing loops. These interactions jointly dictate cellular fates (senescence and cell death programs), which are sustained by “metabolic memory” to drive progressive structural remodeling. The integration of these unidirectional pathways creates a self-amplifying cycle that maintains chronic myocardial injury beyond a simple linear cascade.
Figure 1. The interconnected pathophysiological network of diabetic cardiomyopathy (DCM). This schematic delineates a non-linear network where metabolic disturbances (glucolipotoxicity and AGEs) and cellular stressors (mitochondrial dysfunction, inflammation, and impaired calcium handling) form mutually reinforcing loops. These interactions jointly dictate cellular fates (senescence and cell death programs), which are sustained by “metabolic memory” to drive progressive structural remodeling. The integration of these unidirectional pathways creates a self-amplifying cycle that maintains chronic myocardial injury beyond a simple linear cascade.

2.5 Cardiac autonomic neuropathy

Diabetes frequently leads to cardiac autonomic imbalance, characterized by increased sympathetic tone and reduced parasympathetic activity (71). Long-term sympathetic overactivation via β-adrenergic receptors increases myocardial oxygen consumption, promotes pathological hypertrophy and fibrosis, and predisposes to arrhythmias—an important component of the overall DCM pathophysiological network (72–77).

3 Networked interactions and emerging integrative concepts

3.1 Cross-talk and feedback loops among core mechanisms

The pathogenesis of DCM is a dynamic system with extensive cross-talk. Oxidative stress and inflammation amplify each other: ROS activate NF-κB and the NLRP3 inflammasome; conversely, activated inflammatory cells produce large amounts of ROS (57, 78–81) Metabolism and inflammation engage in vicious cross-talk: inflammatory cytokines induce local insulin resistance, while inflammation-driven fibrosis alters myocardial stiffness and perfusion, exacerbating energy crisis (82–84) Cell death and inflammation promote each other: necroptosis releases DAMPs, activating immune responses, while a persistent inflammatory milieu makes surviving cardiomyocytes more prone to cell death (57). Mitochondria serve as a central hub, releasing molecules (e.g. mitochondrial DNA) that act as DAMPs, thus connecting metabolic disturbances, oxidative stress, and inflammation (85, 86). Metabolic-structural coupling and metabolic memory are also interrelated, because directly disrupting myofilament proteins may lead to epigenetic changes, while continuous epigenetic modifications may enable the expression of pathogenic metabolic molecules to be maintained. A comprehensive visualization of these networked interactions and emerging concepts is provided in Figure 1.

3.2 “Metabolic–structural coupling”: from signal interference to direct physical disruption

The emerging “metabolic–structural coupling” hypothesis proposes a direct injury model. A recent study found that in diabetic myocardium, the lipid metabolism molecule acyl-CoA binding protein (ACBP) is upregulated and aberrantly binds to the core sarcomeric structural protein, cardiac myosin-binding protein C (MyBPC3). This abnormal binding physically interferes with MyBPC3’s function, directly compromising cross-bridge cycling efficiency (87). This discovery provides a new dimension for understanding how metabolic disturbances directly lead to decreased myocardial mechanical performance. This concept suggests that physical interactions between metabolites and structural proteins could serve as novel biomarkers for early DCM diagnosis, beyond soluble signaling molecules. Moreover, targeting ACBP or its binding interface with MyBPC3 might offer a therapeutic strategy to directly restore myocardial contractility, independent of traditional metabolic or inflammatory pathways. In addition to the acute insulin resistance plasma protein (ACBP), intermediate products of glycolysis such as methylglyoxal and lactic acid can directly modify myofilament proteins through glycosylation and lactoylation. The lactoylation of histones driven by lactic acid provides a direct link to the metabolic memory mechanism. In this mechanism, these epigenetic marks persist even after blood sugar returns to normal and encode long-term functional disorders.

3.3 “Metabolic memory”: the persistent imprint of injury and epigenetic basis

The “metabolic memory” phenomenon, where tissue injury progresses even after normalization of hyperglycemia, is a major clinical challenge. A key pathway has been revealed: hyperglycemia induces sustained release of small extracellular vesicles (sEVs) enriched with the miR-15–16 cluster from endothelial cells. These vesicles are taken up by cardiomyocytes, leading to long-term activation of CaMKIIδ and increased O-GlcNAc modification, persistently driving dysfunction (6). Intensive glucose lowering in late-stage DCM may offer diminishing returns because the memory is already “encoded” epigenetically. This positions early glycemic control and interventions that reverse epigenetic marks as priority research avenues. Beyond the heart, similar interactions mediated by extracellular vesicles are likely to occur between the heart of diabetic patients and distant organs (liver, adipose tissue, skeletal muscle). These interactions will spread metabolic memory throughout the body, thereby explaining why dilated cardiomyopathy often coexists with other diabetic complications. This explains the limited benefit of late intensive glucose-lowering and underscores the critical importance of early intervention. From a clinical perspective, metabolic memory highlights the need for risk stratification based on epigenetic markers. Circulating sEVs carrying specific miRNA signatures could serve as non-invasive biomarkers to identify patients at high risk for progressive DCM despite glycemic control. Therapeutically, interventions that block sEV generation or uptake, or reverse detrimental epigenetic modifications, may break the memory loop and halt disease progression. The ATAC-seq study in the model of dilated cardiomyopathy revealed the dynamic changes in chromatin accessibility, which were associated with the changes in gene expression in metabolic and contractile pathways. This provided a direct molecular basis for how metabolic memory is “encoded” at the chromatin level and offered the possibility of potential epigenetic targets for therapeutic reversal. Therefore, metabolic memory has the ability to integrate the states of the entire system at different time points. This characteristic explains why metabolic disorders that occur early, even after blood sugar levels return to normal, still persist and cause mitochondrial dysfunction and inflammatory responses. From a clinical perspective, this mechanism of metabolic memory prompts us to redefine dilated cardiomyopathy as a disease with “time-dependent” characteristics. In such diseases, early intervention measures can achieve particularly significant therapeutic effects.

4 Clinical heterogeneity of DCM: rethinking mechanisms and therapeutic implications

DCM is not a homogeneous disease. In type 1 diabetes (T1DM)-related DCM, mechanisms may be more focused on “glucotoxicity”. (88) Therefore, early strict glycemic control may be more decisive for prevention (89). In contrast, type 2 diabetes (T2DM)-related DCM is more prominently characterized by “insulin resistance” and “lipotoxicity”. (90–92).

Age also influences DCM. Early-onset diabetes exposes patients to metabolic abnormalities for longer, making “metabolic memory” effects more significant (93–95) In late-onset diabetes, DCM interacts with age-related cardiac changes, making the disease course more complex (96–99) Comorbidities like obesity and chronic kidney disease (CKD) are significant aggravating factors, forming a complex cardiorenal–metabolic syndrome (100–108).

5 Emerging therapeutic strategies

First, it must be recognized that lifestyle intervention measures such as calorie restriction, aerobic exercise, resistance training, and weight management remain the key foundation for the prevention and management of dilated cardiomyopathy. These interventions can directly enhance myocardial sensitivity to insulin, reduce lipotoxicity, and alleviate oxidative stress and inflammation. Weight loss can improve diastolic function in patients with obesity and diabetes. Based on the following treatment framework, which is the adjustment of lifestyle, drug therapy and experimental strategies are superimposed. Given the clinical heterogeneity discussed above, therapeutic approaches must be tailored to individual patient profiles. For example, obese T2DM patients may particularly benefit from therapies targeting lipid droplet dynamics and farnesoid X receptor (FXR) activation, while elderly patients with cellular senescence might be prime candidates for senolytics. Below we review the key emerging strategies.

5.1 Pleiotropic network effects of SGLT2 inhibitors

SGLT2 inhibitors (SGLT2i) exhibit multilayered network regulation. Their direct effects include inhibiting renal SGLT2 and myocardial sodium-hydrogen exchanger (NHE), improving energy metabolism (109). At an intermediate level, they activate autophagy, restore mitophagy, and upregulate NRF2, thereby inhibiting ferroptosis (32, 33). These actions lead to downstream outcomes of reduced inflammation and fibrosis. Clinical trials like EMPA-REG OUTCOME, DAPA-HF, and others consistently demonstrate their cardiovascular benefits (Table 1). SGLT2i represent a prototypic network-based therapy that simultaneously targets multiple core DCM pathways. However, most of the experimental data come from patients who already have heart failure, rather than from patients with early DCM. This creates a critical gap in primary prevention. The challenges in the translational aspect mainly lie in the lack of comprehensive preclinical models that fully represent the heterogeneity of human DCM, as well as the uncertainty regarding the optimal dose. Emerging evidence suggests SGLT2i may reverse certain epigenetic marks associated with metabolic memory, though direct effects on metabolic-structural coupling remain unexplored. Additionally, there is an urgent need to conduct randomized controlled trials and the determination of mechanistic biomarkers.

Table 1. Key clinical trial evidence for SGLT2i and GLP-1RA in diabetic populations.

Therapy classKey trialsMain CV outcomes (DCM-relevant)
SGLT2 inhibitorsEMPA-REG OUTCOME (empagliflozin), DAPA-HF (dapagliflozin)HF hospitalization ↓, CV death ↓, benefit independent of glucose lowering
GLP-1 receptor agonistsSOUL Randomized TrialMACE ↓, atherosclerotic events ↓, modest effect on HF hospitalization

5.2 Cardiovascular protective effects of GLP-1 receptor agonists

GLP-1 receptor agonists (GLP-1RAs) reduce inflammation and oxidative stress, inhibit apoptosis, and improve endothelial function (110, 111). Clinical data show they reduce major adverse cardiovascular events (MACE), particularly atherosclerotic events, though their effect on heart failure hospitalization is less pronounced than SGLT2i (Table 1; 112–117) This differential efficacy underscores the need to match therapy to patient phenotype: GLP-1RAs may be preferred in DCM patients with predominant macrovascular disease, whereas SGLT2i might be more suitable for those with heart failure risk. At present, there are significant clinical trial gaps in the relevant research field, namely, no specific clinical trials have been conducted that focus on the target endpoints of DCM (without considering major vascular events) as evaluation indicators. Moreover, the translational application potential of GLP-1RAs in the treatment of DCM is limited by two factors. One is the issue of gastrointestinal tolerance in patients, and the other is the lack of preclinical models that can precisely reproduce the heterogeneity of human DCM. In particular, it is important to note that the DCM patients with normal weight constitute a large subpopulation, and currently there is a lack of clear clinical evidence to support the relevant treatment strategies.

5.3 Emerging therapies targeting ferroptosis

Irisin, a myokine, has been shown in preclinical studies to inhibit ferroptosis by activating the System Xc-/GSH/GPX4 axis (118, 119). Other muscle cell factors and liver factors also influence the progression of dilated cardiomyopathy. In this systemic network, skeletal muscles and the liver communicate with the heart through endocrine mediators. Alpha-lipoic acid (ALA) demonstrated significant efficacy in a small randomized controlled trial in patients with T2DM and ischemic cardiomyopathy, reducing inflammatory and fibrotic markers and improving cardiac function (120). Given that ferroptosis may play a more prominent role in advanced DCM, these agents could be particularly valuable for patients with established heart failure. However, the ALA trial was of a relatively small scale (with a sample size of only 67 cases), and it was conducted in patients with ischemic cardiomyopathy rather than purely dilated cardiomyopathy patients. The key gaps in translational research include the lack of specific ferroptosis biomarkers for patient screening, as well as the unclear long-term safety of chronic GPX4 pathway regulation. Whether ferroptosis inhibitors affect metabolic-structural coupling (e.g. by reducing ACBP expression or preventing its binding to MyBPC3) or reverse epigenetic memory marks remains unknown and warrants future investigation.

5.4 Senolytics: clearing senescent cells

Senolytics like dasatinib and quercetin (D+Q) have shown promise in animal models of DCM, clearing senescent cells and alleviating SASP-related inflammation (121, 122). Direct clinical evidence in DCM is insufficient, but trials in diabetic kidney disease support the safety and feasibility of this approach (123). In late-onset diabetes, where cellular senescence is accelerated, senolytics could mitigate age-related cardiac deterioration and improve regenerative capacity. Despite this, direct clinical evidence in DCM is absent, no trial has reported DCM-specific outcomes. Major limitations include off-target effects on non-senescent cells, unknown dosing regimens for cardiac versus renal indications, and the lack of validated senescence biomarkers to guide therapy initiation and monitoring. Senolytics could theoretically interrupt metabolic-structural coupling by eliminating senescent cells that secrete ACBP or other pathogenic metabolites, and may also reset epigenetic clocks, but direct experimental evidence is lacking.

5.5 Emerging targets: lipid droplet dynamics and FXR receptor

Targeting lipid droplet homeostasis is a new frontier (124, 125). Similarly, the farnesoid X receptor (FXR) is a key regulator of metabolism and inflammation. Obeticholic acid (OCA), an FXR agonist, has shown cardioprotective effects in preclinical models by activating the FXR/Nrf2 pathway (126–128). For obese T2DM patients with pronounced lipotoxicity, modulating lipid droplets and activating FXR might synergistically alleviate cardiac lipid overload and inflammation.

6 Conclusions and future directions

DCM pathogenesis has evolved into a complex dynamic network. The emerging concepts of “metabolic–structural coupling” and “metabolic memory” reveal underlying reasons for the limitations of previous therapies. Targeting ferroptosis, cellular senescence, and metabolic regulators like FXR are promising new directions.

However, these strategies face challenges: most targets lack human validation, clinical trial evidence is often from small samples, and the clinical heterogeneity of DCM demands better biomarkers for precise stratification. Within this framework, metabolic-structural coupling explains how metabolic stress directly impairs contraction, while metabolic memory accounts for disease persistence despite glucose control—together bridging molecular pathways to clinical phenotypes. Future research must apply multi-omics technologies to human samples and develop more representative disease models to accelerate preclinical validation. The ultimate goal is a paradigm shift from “one disease, one treatment” to “one disease, multiple subtypes, personalized therapy”.

Generative AI statement

The author(s) declared that generative AI was not used in the creation of this manuscript.

Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Footnotes

Edited by: Hemant Giri, Excitant Therapeutics LLC, United States

Reviewed by: Pamela Senesi, MultiMedica (IRCCS), Italy

Rahul Rajala, University of Oklahoma Health Sciences Center, United States

Nawfal Hasan Siam, Independent University, Bangladesh

Statements

Conflict of interest

The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Funding

The author(s) declared that financial support was received for this work and/or its publication. This work was supported by grants from the National Natural Science Foundation of China (No. 82400343), the National Radiology and Therapy Clinical Medical Research Center Jiangxi Branch Center (20241ZDG02056). The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.

Author contributions

HR: Writing – original draft, Conceptualization. HL: Writing – review & editing, Funding acquisition, Conceptualization.

References

  1. 1 Ritchie RH, Abel ED. Basic mechanisms of diabetic heart disease. Circulation Research. (2020) 126: 1501–1525. doi:. PMID: doi:10.1161/CIRCRESAHA.120.315913
  2. 2 Ernande L, Derumeaux G. Diabetic cardiomyopathy: myth or reality?. Archives of Cardiovascular Diseases. (2012) 105: 218–225. doi:. PMID: doi:10.1016/j.acvd.2011.11.007
  3. 3 Jia G, DeMarco VG, Sowers JR. Insulin resistance and hyperinsulinaemia in diabetic cardiomyopathy. Nature Reviews Endocrinology. (2016) 12: 144–153. doi:. PMID: doi:10.1038/nrendo.2015.216
  4. 4 Luo L, Wu Q, Xiao Q, Chen Y, Deng Z, Cen C. Lipotoxicity-induced upregulation of FIS1 exacerbates mitochondrial fragmentation and promotes NLRP3-dependent pyroptosis in diabetic cardiomyopathy. Free Radical Biology and Medicine. (2025) 228: 183–196. doi:. PMID: doi:10.1016/j.freeradbiomed.2024.12.049
  5. 5 Zlobine I, Gopal K, Ussher JR. Lipotoxicity in obesity and diabetes-related cardiac dysfunction. Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids. (2016) 1861: 1555–1568. doi:. PMID: doi:10.1016/j.bbalip.2016.02.011
  6. 6 Ding M, Shi R, Du Y, Chang P, Gao T, De D. O-GlcNAcylation-mediated endothelial metabolic memory contributes to cardiac damage via small extracellular vesicles. Cell Metabolism. (2025) 37: 1344–1363.e6. doi:. PMID: doi:10.1016/j.cmet.2025.03.006
  7. 7 Jing H, Shi M, Wang Y, Cao R, Li X, Zhong X. β-Hydroxybutyrylation links ketone metabolism to mitochondrial remodeling in diabetic cardiomyopathy. Diabetes. (2026) 75: 37–50. doi:. PMID: doi:10.2337/db25-0496
  8. 8 Fan Y, Yan Z, Li T, Li A, Fan X, Qi Z. Primordial drivers of diabetes heart disease: comprehensive insights into insulin resistance. Diabetes and Metabolism Journal. (2024) 48: 19–36. doi:. PMID: doi:10.4093/dmj.2023.0110
  9. 9 Hu F, Li Z, Li Y, Zhi Y, Tang T, Wang P. EGLN1 inhibition reverses angiogenesis impairment in hyperglycemia by activating autophagy. Scientific Reports. (2025) 15: 35804. doi:. PMID: doi:10.1038/s41598-025-19745-6
  10. 10 Lopaschuk GD, Karwi QG, Tian R, Wende AR, Abel ED. Cardiac energy metabolism in heart failure. Circulation Research. (2021) 128: 1487–1513. doi:. PMID: doi:10.1161/CIRCRESAHA.121.318241
  11. 11 Actis Dato V, Lange S, Cho Y. Metabolic flexibility of the heart: the role of fatty acid metabolism in health, heart failure, and cardiometabolic diseases. International Journal of Molecular Sciences. (2024) 25: 1211. doi:. PMID: doi:10.3390/ijms25021211
  12. 12 Oates PJ. Polyol pathway and diabetic peripheral neuropathy. International Review of Neurobiology. (2002) 50: 325–392. doi:. PMID: doi:10.1016/s0074-7742(02)50082-9
  13. 13 Riehle C, Bauersachs J. Of mice and men: models and mechanisms of diabetic cardiomyopathy. Basic Research in Cardiology. (2018) 114: 2. doi:. PMID: doi:10.1007/s00395-018-0711-0
  14. 14 Garg SS, Gupta J. Polyol pathway and redox balance in diabetes. Pharmacological Research. (2022) 182: 106326. doi:. PMID: doi:10.1016/j.phrs.2022.106326
  15. 15 Avagimyan A, Popov S, Shalnova S. The pathophysiological basis of diabetic cardiomyopathy development. Current Problems in Cardiology. (2022) 47: 101156. doi:. PMID: doi:10.1016/j.cpcardiol.2022.101156
  16. 16 Jannapureddy S, Sharma M, Yepuri G, Schmidt AM, Ramasamy R. Aldose reductase: an emerging target for development of interventions for diabetic cardiovascular complications. Frontiers in Endocrinology (Lausanne). (2021) 12: 636267. doi:. PMID: doi:10.3389/fendo.2021.636267
  17. 17 Jin X, Yao T, Zhou Z, Zhu J, Zhang S, Hu W. Advanced glycation end products enhance macrophages polarization into M1 phenotype through activating RAGE/NF-κB pathway. BioMed Research International. (2015) 2015: 732450. doi:. PMID: doi:10.1155/2015/732450
  18. 18 Geraldes P, King GL. Activation of protein kinase C isoforms and its impact on diabetic complications. Circulation Research. (2010) 106: 1319–1331. doi:. PMID: doi:10.1161/CIRCRESAHA.110.217117
  19. 19 Makino A, Dai A, Han Y, Youssef KD, Wang W, Donthamsetty R. O-GlcNAcase overexpression reverses coronary endothelial cell dysfunction in type 1 diabetic mice. American Journal of Physiology-Cell Physiology. (2015) 309: C593–C599. doi:. PMID: doi:10.1152/ajpcell.00069.2015
  20. 20 Bekhite M, González-Delgado A, Hübner S, Haxhikadrija P, Kretzschmar T, Müller T. The role of ceramide accumulation in human induced pluripotent stem cell-derived cardiomyocytes on mitochondrial oxidative stress and mitophagy. Free Radical Biology and Medicine. (2021) 167: 66–80. doi:. PMID: doi:10.1016/j.freeradbiomed.2021.02.016
  21. 21 Birkenfeld AL, Shulman GI. Nonalcoholic fatty liver disease, hepatic insulin resistance, and type 2 diabetes. Hepatology. (2014) 59: 713–723. doi:. PMID: doi:10.1002/hep.26672
  22. 22 Rask-Madsen C, King GL. Proatherosclerotic mechanisms involving protein kinase C in diabetes and insulin resistance. Arteriosclerosis, Thrombosis, and Vascular Biology. (2005) 25: 487–496. doi:. PMID: doi:10.1161/01.ATV.0000155325.41507.e0
  23. 23 Zorova LD, Popkov VA, Plotnikov EY, Silachev DN, Pevzner IB, Jankauskas SS. Mitochondrial membrane potential. Analytical Biochemistry. (2018) 552: 50–59. doi:. PMID: doi:10.1016/j.ab.2017.07.009
  24. 24 Wang Y, Wang Y, Li F, Zhang X, Li H, Yang G. Spermine protects cardiomyocytes from high glucose-induced energy disturbance by targeting the CaSR-gp78-ubiquitin proteasome system. Cardiovascular Drugs and Therapy. (2021) 35: 73–85. doi:. PMID: doi:10.1007/s10557-020-07064-z
  25. 25 Zhi F, Pu X, Wei W, Liu L, Liu C, Chen Y. Modulating mitochondrial dynamics ameliorates left ventricular dysfunction by suppressing diverse cell death pathways after diabetic cardiomyopathy. International Journal of Medical Sciences. (2024) 21: 2324–2333. doi:. PMID: doi:10.7150/ijms.98065
  26. 26 Tokuyama T, Yanagi S. Role of mitochondrial dynamics in heart diseases. Genes (Basel). (2023) 14: 1876. doi:. PMID: doi:10.3390/genes14101876
  27. 27 Wu QR, Zheng DL, Liu PM, Yang H, Li LA, Kuang SJ. High glucose induces Drp1-mediated mitochondrial fission via the Orai1 calcium channel to participate in diabetic cardiomyocyte hypertrophy. Cell Death and Disease. (2021) 12: 216. doi:. PMID: doi:10.1038/s41419-021-03502-4
  28. 28 Fan X, Li X, Liu H, Xu F, Ji X, Chen Y. A ROCK1 inhibitor fasudil alleviates cardiomyocyte apoptosis in diabetic cardiomyopathy by inhibiting mitochondrial fission in a type 2 diabetes mouse model. Frontiers in Pharmacology. (2022) 13: 892643. doi:. PMID: doi:10.3389/fphar.2022.892643
  29. 29 Byrne NJ, Rajasekaran NS, Abel ED, Bugger H. Therapeutic potential of targeting oxidative stress in diabetic cardiomyopathy. Free Radical Biology and Medicine. (2021) 169: 317–342. doi:. PMID: doi:10.1016/j.freeradbiomed.2021.03.046
  30. 30 Jaishy B, Zhang Q, Chung HS, Riehle C, Soto J, Jenkins S. Lipid-induced NOX2 activation inhibits autophagic flux by impairing lysosomal enzyme activity. Journal of Lipid Research. (2015) 56: 546–561. doi:. PMID: doi:10.1194/jlr.M055152
  31. 31 Yan M, Li Y, Luo Q, Zeng W, Shao X, Li L. Mitochondrial damage and activation of the cytosolic DNA sensor cGAS-STING pathway lead to cardiac pyroptosis and hypertrophy in diabetic cardiomyopathy mice. Cell Death Discovery. (2022) 8: 258. doi:. PMID: doi:10.1038/s41420-022-01046-w
  32. 32 Yang C, Xiao C, Ding Z, Zhai X, Liu J, Yu M. Canagliflozin mitigates diabetic cardiomyopathy through enhanced PINK1-Parkin mitophagy. International Journal of Molecular Sciences. (2024) 25: 7008. doi:. PMID: doi:10.3390/ijms25137008
  33. 33 Yang N, Zhang R, Zhang H, Yu Y, Xu Z. ZIP7 contributes to the pathogenesis of diabetic cardiomyopathy by suppressing mitophagy in mouse hearts. Cardiovascular Diabetology. (2024) 23: 399. doi:. PMID: doi:10.1186/s12933-024-02499-2
  34. 34 Mu J, Zhang D, Tian Y, Xie Z, Zou MH. BRD4 inhibition by JQ1 prevents high-fat diet-induced diabetic cardiomyopathy by activating PINK1/Parkin-mediated mitophagy in vivo. Journal of Molecular and Cellular Cardiology. (2020) 149: 1–14. doi:. PMID: doi:10.1016/j.yjmcc.2020.09.003
  35. 35 Nag S, Mitra O, Maturi B, Kaur SP, Saini A, Nama M. Autophagy and mitophagy as potential therapeutic targets in diabetic heart condition: harnessing the power of nanotheranostics. Asian Journal of Pharmaceutical Sciences. (2024) 19: 100927. doi:. PMID: doi:10.1016/j.ajps.2024.100927
  36. 36 Tong M, Saito T, Zhai P, Oka SI, Mizushima W, Nakamura M. Mitophagy is essential for maintaining cardiac function during high fat diet-induced diabetic cardiomyopathy. Circulation Research. (2019) 124: 1360–1371. doi:. PMID: doi:10.1161/CIRCRESAHA.118.314607
  37. 37 Rezaee A, Rahmanian P, Nemati A, Sohrabifard F, Karimi F, Elahinia A. NF-κB axis in diabetic neuropathy, cardiomyopathy and nephropathy: a roadmap from molecular intervention to therapeutic strategies. Heliyon. (2024) 10: e29871. doi:. PMID: doi:10.1016/j.heliyon.2024.e29871
  38. 38 Belali OM, Ahmed MM, Mohany M, Belali TM, Alotaibi MM, Al-Hoshani A. LCZ696 protects against diabetic cardiomyopathy-induced myocardial inflammation, ER stress, and apoptosis through inhibiting AGEs/NF-κB and PERK/CHOP signaling pathways. International Journal of Molecular Sciences. (2022) 23: 1288. doi:. PMID: doi:10.3390/ijms23031288
  39. 39 Qiao YC, Shen J, He L, Hong XZ, Tian F, Pan YH. Changes of regulatory T cells and of proinflammatory and immunosuppressive cytokines in patients with type 2 diabetes mellitus: a systematic review and meta-analysis. Journal of Diabetes Research. (2016) 2016: 3694957. doi:. PMID: doi:10.1155/2016/3694957
  40. 40 Gao W, Liang L. Effect of polysaccharide sulfate-loaded poly(lactic-co-glycolic acid) nanoparticles on coronary microvascular dysfunction of diabetic cardiomyopathy. Journal of Biomedical Nanotechnology. (2022) 18: 446–452. doi:. PMID: doi:10.1166/jbn.2022.3261
  41. 41 Stevens SA, Sunilkumar S, Subrahmanian SM, Toro AL, Cavus O, Omorogbe EV. REDD1 deletion suppresses NF-κB signaling in cardiomyocytes and prevents deficits in cardiac function in diabetic mice. International Journal of Molecular Sciences. (2024) 25: 6461. doi:. PMID: doi:10.3390/ijms25126461
  42. 42 Qu XF, Zhai BZ, Hu WL, Lou MH, Chen YH, Liu YF. Pyrroloquinoline quinone ameliorates diabetic cardiomyopathy by inhibiting the pyroptosis signaling pathway in C57BL/6 mice and AC16 cells. European Journal of Nutrition. (2022) 61: 1823–1836. doi:. PMID: doi:10.1007/s00394-021-02768-w
  43. 43 Chen J, Chen ZJ. PtdIns4P on dispersed trans-Golgi network mediates NLRP3 inflammasome activation. Nature. (2018) 564: 71–76. doi:. PMID: doi:10.1038/s41586-018-0761-3
  44. 44 Luo B, Li B, Wang W, Liu X, Xia Y, Zhang C. NLRP3 gene silencing ameliorates diabetic cardiomyopathy in a type 2 diabetes rat model. PLoS One. (2014) 9: e104771. doi:. PMID: doi:10.1371/journal.pone.0104771
  45. 45 Wang Y, Lin Q, Zhang H, Wang S, Cui J, Hu Y. M2 macrophage-derived exosomes promote diabetic fracture healing by acting as an immunomodulator. Bioactive Materials. (2023) 28: 273–283. doi:. PMID: doi:10.1016/j.bioactmat.2023.05.018
  46. 46 Xing Y, Sun X, Dou Y, Wang M, Zhao Y, Yang Q. The immuno-modulation effect of macrophage-derived extracellular vesicles in chronic inflammatory diseases. Frontiers in Immunology. (2021) 12: 785728. doi: doi:10.3389/fimmu.2021.785728
  47. 47 Liu Y, Zhang J, Han Q, Li Y, Xue Y, Liu X. Identification of biomarkers associated with macrophage polarization in diabetic cardiomyopathy based on bioinformatics and machine learning approaches. Life Sciences. (2025) 364: 123443. doi:. PMID: doi:10.1016/j.lfs.2025.123443
  48. 48 Wynn TA, Vannella KM. Macrophages in tissue repair, regeneration, and fibrosis. Immunity. (2016) 44: 450–462. doi:. PMID: doi:10.1016/j.immuni.2016.02.015
  49. 49 Mouton AJ, Li X, Hall ME, Hall JE. Obesity, hypertension, and cardiac dysfunction: novel roles of immunometabolism in macrophage activation and inflammation. Circulation Research. (2020) 126: 789–806. doi:. PMID: doi:10.1161/CIRCRESAHA.119.312321
  50. 50 Li X, Yang L, Xu S, Tian Y, Meng X. Exosomes and macrophages: bidirectional mutual regulation in the treatment of diabetic complications. Cellular and Molecular Bioengineering. (2024) 17: 243–261. doi:. PMID: doi:10.1007/s12195-024-00816-z
  51. 51 Yue Y, Meng K, Pu Y, Zhang X. Transforming growth factor beta (TGF-β) mediates cardiac fibrosis and induces diabetic cardiomyopathy. Diabetes Research and Clinical Practice. (2017) 133: 124–130. doi:. PMID: doi:10.1016/j.diabres.2017.08.018
  52. 52 Lafuse WP, Wozniak DJ, Rajaram MVS. Role of cardiac macrophages on cardiac inflammation, fibrosis and tissue repair. Cells. (2020) 10: 51. doi:. PMID: doi:10.3390/cells10010051
  53. 53 Morey M, O'Gaora P, Pandit A, Hélary C. Hyperglycemia acts in synergy with hypoxia to maintain the pro-inflammatory phenotype of macrophages. PLoS One. (2019) 14: e0220577. doi:. PMID: doi:10.1371/journal.pone.0220577
  54. 54 Alipourfard I, Datukishvili N, Mikeladze D. TNF-α downregulation modifies insulin receptor substrate 1 (IRS-1) in metabolic signaling of diabetic insulin-resistant hepatocytes. Mediators of Inflammation. (2019) 2019: 3560819. doi:. PMID: doi:10.1155/2019/3560819
  55. 55 Cheng YC, Chiu YM, Dai ZK, Wu BN. Loganin ameliorates painful diabetic neuropathy by modulating oxidative stress, inflammation and insulin sensitivity in streptozotocin-nicotinamide-induced diabetic rats. Cells. (2021) 10: 2688. doi:. PMID: doi:10.3390/cells10102688
  56. 56 Tait SWG, Green DR. Mitochondria and cell death: outer membrane permeabilization and beyond. Nature Reviews Molecular Cell Biology. (2010) 11: 621–632. doi:. PMID: doi:10.1038/nrm2952
  57. 57 Lu Y, Cui J, Cheng X, Li J, Zhang L, Tian J. Regulated cell death and inflammatory signaling in diabetic cardiomyopathy: mechanisms and therapeutic strategies. Journal of Cardiovascular Translational Research. (2025) 18: 1902–1923. doi:. PMID: doi:10.1007/s12265-025-10701-3
  58. 58 Wei J, Zhao Y, Liang H, Du W, Wang L. Preliminary evidence for the presence of multiple forms of cell death in diabetes cardiomyopathy. Acta Pharmaceutica Sinica B. (2022) 12: 1–17. doi:. PMID: doi:10.1016/j.apsb.2021.08.026
  59. 59 Li J, Wang H. Autophagy-dependent ferroptosis in infectious disease. Journal of Translational Internal Medicine. (2023) 11: 355–362. doi:. PMID: doi:10.2478/jtim-2023-0099
  60. 60 Zhang Z, Bai X, Du Q, Yang J. α-Linolenic acid alleviates diabetic cardiomyopathy by activating AMPK-STAT3 pathway to inhibit ferritinophagy and enhance SLC7A11-GPX4 antioxidant axis. Molecules. (2025) 31: 79. doi:. PMID: doi:10.3390/molecules31010079
  61. 61 Xiang H, Lyu Q, Chen S, Ouyang J, Xiao D, Liu Q. PACS2/CPT1A/DHODH signaling promotes cardiomyocyte ferroptosis in diabetic cardiomyopathy. Cardiovascular Diabetology. (2024) 23: 432. doi:. PMID: doi:10.1186/s12933-024-02514-6
  62. 62 Yu Y, Yan Y, Niu F, Wang Y, Chen X, Su G. Ferroptosis: a cell death connecting oxidative stress, inflammation and cardiovascular diseases. Cell Death Discovery. (2021) 7: 193. doi:. PMID: doi:10.1038/s41420-021-00579-w
  63. 63 Gu J, Wang S, Guo H, Tan Y, Liang Y, Feng A. Inhibition of p53 prevents diabetic cardiomyopathy by preventing early-stage apoptosis and cell senescence, reduced glycolysis, and impaired angiogenesis. Cell Death and Disease. (2018) 9: 82. doi:. PMID: doi:10.1038/s41419-017-0093-5
  64. 64 Wu L, Zhu X, Pan S, Chen Y, Luo C, Zhao Y. Diabetes advances cardiomyocyte senescence through interfering Rnd3 expression and function. Aging Cell. (2025) 24: e70031. doi:. PMID: doi:10.1111/acel.70031
  65. 65 Li H, Hastings MH, Rhee J, Trager LE, Roh JD, Rosenzweig A. Targeting age-related pathways in heart failure. Circulation Research. (2020) 126: 533–551. doi:. PMID: doi:10.1161/CIRCRESAHA.119.315889
  66. 66 Wen Y, Zhang X, Liu H, Ye H, Wang R, Ma C. SGLT2 inhibitor downregulates ANGPTL4 to mitigate pathological aging of cardiomyocytes induced by type 2 diabetes. Cardiovascular Diabetology. (2024) 23: 430. doi:. PMID: doi:10.1186/s12933-024-02520-8
  67. 67 Saucerman JJ, Tan PM, Buchholz KS, McCulloch AD, Omens JH. Mechanical regulation of gene expression in cardiac myocytes and fibroblasts. Nature Reviews Cardiology. (2019) 16: 361–378. doi:. PMID: doi:10.1038/s41569-019-0155-8
  68. 68 Song S, Liu L, Yu Y, Zhang R, Li Y, Cao W. Inhibition of BRD4 attenuates transverse aortic constriction- and TGF-β-induced endothelial-mesenchymal transition and cardiac fibrosis. Journal of Molecular and Cellular Cardiology. (2019) 127: 83–96. doi:. PMID: doi:10.1016/j.yjmcc.2018.12.002
  69. 69 Kang S, Majid A, Hammoudi N, Lebeche D. Gene and drug-mediated SERCA2a activation restores cardiac function and metabolic balance in diabetic mice. Biomedicine and Pharmacotherapy. (2025) 192: 118617. doi:. PMID: doi:10.1016/j.biopha.2025.118617
  70. 70 Kim OH, Noh SW, Choi JS, Jung Y, Oh BC. The SERCA-PLN-DWORF axis in cardiometabolic disease: mechanisms and therapeutic perspectives. Cardiovascular Diabetology. (2025) 25: 17. doi:. PMID: doi:10.1186/s12933-025-03023-w
  71. 71 Dell'Oro R, Quarti-Trevano F, Ciardullo S, Perseghin G, Mancia G, Grassi G. Reliability of heart rate in reflecting cardiac sympathetic overdrive in type 2 diabetes mellitus. Clinical Autonomic Research. (2024) 34: 437–445. doi:. PMID: doi:10.1007/s10286-024-01054-z
  72. 72 Russo I, Frangogiannis NG. Diabetes-associated cardiac fibrosis: cellular effectors, molecular mechanisms and therapeutic opportunities. Journal of Molecular and Cellular Cardiology. (2016) 90: 84–93. doi:. PMID: doi:10.1016/j.yjmcc.2015.12.011
  73. 73 Jia G, Hill MA, Sowers JR. Diabetic cardiomyopathy: an update of mechanisms contributing to this clinical entity. Circulation Research. (2018) 122: 624–638. doi:. PMID: doi:10.1161/CIRCRESAHA.117.311586
  74. 74 Murtaza G, Virk HUH, Khalid M, Lavie CJ, Ventura H, Mukherjee D. Diabetic cardiomyopathy - a comprehensive updated review. Progress in Cardiovascular Diseases. (2019) 62: 315–326. doi:. PMID: doi:10.1016/j.pcad.2019.03.003
  75. 75 Sudo SZ, Montagnoli TL, Rocha BDS, Santos AD, de Sá MPL, Zapata-Sudo G. Diabetes-induced cardiac autonomic neuropathy: impact on heart function and prognosis. Biomedicines. (2022) 10: 3258. doi:. PMID: doi:10.3390/biomedicines10123258
  76. 76 Tannus LRM, Cobas RA. Autonomic neuropathy in diabetes. Archives of Endocrinology and Metabolism. (2025) 70: e250406. doi: doi:10.20945/2359-4292-2025-0406
  77. 77 Eleftheriadou A, Spallone V, Tahrani AA, Alam U. Cardiovascular autonomic neuropathy in diabetes: an update with a focus on management. Diabetologia. (2024) 67: 2611–2625. doi:. PMID: doi:10.1007/s00125-024-06242-0
  78. 78 Yang D, Ruan H, Chen L, Zhang H, Liu G. Pituitary adenylate cyclase-activating polypeptide (PACAP) attenuates diabetic cardiomyopathy via Nrf2/HO-1 antioxidant signaling and NF-κB-mediated inflammation suppression in streptozotocin-treated mice. Neuropeptides. (2025) 114: 102568. doi:. PMID: doi:10.1016/j.npep.2025.102568
  79. 79 Chen MY, Meng XF, Han YP, Yan JL, Xiao C, Qian LB. Profile of crosstalk between glucose and lipid metabolic disturbance and diabetic cardiomyopathy: inflammation and oxidative stress. Frontiers in Endocrinology (Lausanne). (2022) 13: 983713. doi:. PMID: doi:10.3389/fendo.2022.983713
  80. 80 Shah MS, Brownlee M. Molecular and cellular mechanisms of cardiovascular disorders in diabetes. Circulation Research. (2016) 118: 1808–1829. doi:. PMID: doi:10.1161/CIRCRESAHA.116.306923
  81. 81 Luo B, Huang F, Liu Y, Liang Y, Wei Z, Ke H. NLRP3 inflammasome as a molecular marker in diabetic cardiomyopathy. Frontiers in Physiology. (2017) 8: 519. doi:. PMID: doi:10.3389/fphys.2017.00519
  82. 82 Tuleta I, Frangogiannis NG. Diabetic fibrosis. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. (2021) 1867: 166044. doi:. PMID: doi:10.1016/j.bbadis.2020.166044
  83. 83 López B, Ravassa S, Moreno MU, José GS, Beaumont J, González A. Diffuse myocardial fibrosis: mechanisms, diagnosis and therapeutic approaches. Nature Reviews Cardiology. (2021) 18: 479–498. doi:. PMID: doi:10.1038/s41569-020-00504-1
  84. 84 Li XM, Jiang L, Liu X, Guo YK, Li Y, Gao Y. Myocardial interstitial fibrosis and subclinical left ventricular systolic dysfunction in type 2 diabetes mellitus patients with obesity: a 3.0 T MRI study. Cardiovascular Diabetology. (2025) 25: 22. doi:. PMID: doi:10.1186/s12933-025-03025-8
  85. 85 Qiu Y, Huang Y, Chen M, Yang Y, Li X, Zhang W. Mitochondrial DNA in NLRP3 inflammasome activation. International Immunopharmacology. (2022) 108: 108719. doi:. PMID: doi:10.1016/j.intimp.2022.108719
  86. 86 Khwaja B, Thankam FG, Agrawal DK. Mitochondrial DAMPs and altered mitochondrial dynamics in OxLDL burden in atherosclerosis. Molecular and Cellular Biochemistry. (2021) 476: 1915–1928. doi:. PMID: doi:10.1007/s11010-021-04061-0
  87. 87 Wu T, Huang T, Ren H, Shen C, Qian J, Fu X. Metabolic coordination structures contribute to diabetic myocardial dysfunction. Circulation Research. (2025) 136: 946–967. doi:. PMID: doi:10.1161/CIRCRESAHA.124.326044
  88. 88 Cieluch A, Uruska A, Zozulinska-Ziolkiewicz D. Can we prevent mitochondrial dysfunction and diabetic cardiomyopathy in type 1 diabetes mellitus? Pathophysiology and treatment options. International Journal of Molecular Sciences. (2020) 21: 2852. doi:. PMID: doi:10.3390/ijms21082852
  89. 89 Braffett BH, Bebu I, Lorenzi GM, Martin CL, Perkins BA, Gubitosi-Klug R. The NIDDK takes on the complications of type 1 diabetes: the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) study. Diabetes Care. (2025) 48: 1089–100. doi: doi:10.2337/dc24-2885
  90. 90 Giraldo-Gonzalez GC, Roman-Gonzalez A, Cañas F, Garcia A. Molecular mechanisms of type 2 diabetes-related heart disease and therapeutic insights. International Journal of Molecular Sciences. (2025) 26: 4548. doi:. PMID: doi:10.3390/ijms26104548
  91. 91 Huang S, Chen Z, Li H, Zou Y, Wang B, Zhao W. High-fat diet-induced diabetic cardiomyopathy in female zebrafish: cardiac pathology and functional decline mediated by type 2 diabetes. Nutrients. (2025) 17: 2209. doi:. PMID: doi:10.3390/nu17132209
  92. 92 Ke J, Pan J, Lin H, Gu J. Diabetic cardiomyopathy: a brief summary on lipid toxicity. ESC Heart Failure. (2023) 10: 776–790. doi:. PMID: doi:10.1002/ehf2.14224
  93. 93 Luk A, Wild SH, Jones S, Anjana RM, Hivert MF, McCaffrey J. Early-onset type 2 diabetes: the next major diabetes transition. The Lancet. (2025) 405: 2313–2326. doi:. PMID: doi:10.1016/S0140-6736(25)00830-X
  94. 94 Lin B, Coleman RL, Bragg F, Maddaloni E, Holman RR, Adler AI. Younger-onset compared with later-onset type 2 diabetes: an analysis of the UK Prospective Diabetes Study (UKPDS) with up to 30 years of follow-up (UKPDS 92). The Lancet Diabetes and Endocrinology. (2024) 12: 904–914. doi: doi:10.1016/S2213-8587(24)00242-0
  95. 95 Twig G, Zucker I, Afek A, Cukierman-Yaffe T, Bendor CD, Derazne E. Adolescent obesity and early-onset type 2 diabetes. Diabetes Care. (2020) 43: 1487–1495. doi:. PMID: doi:10.2337/dc19-1988
  96. 96 Chaib S, Tchkonia T, Kirkland JL. Obesity, senescence, and senolytics. Handbook of Experimental Pharmacology. (2022) 274: 165–180. doi: doi:10.1007/164_2021_555
  97. 97 Palmer AK, Gustafson B, Kirkland JL, Smith U. Cellular senescence: at the nexus between ageing and diabetes. Diabetologia. (2019) 62: 1835–1841. doi:. PMID: doi:10.1007/s00125-019-4934-x
  98. 98 Yin X, Wei Y, Liu Y, Chen G, Chen J, Cheng J. Reparative effects of VCAM-1 high-performance MSC-derived exosomes on aged diabetic cardiomyocyte injury: a focus on ferroptosis suppression. Apoptosis. (2026) 31: 9. doi:. PMID: doi:10.1007/s10495-025-02224-8
  99. 99 Palmer AK, Xu M, Zhu Y, Pirtskhalava T, Weivoda MM, Hachfeld CM. Targeting senescent cells alleviates obesity-induced metabolic dysfunction. Aging Cell. (2019) 18: e12950. doi:. PMID: doi:10.1111/acel.12950
  100. 100 Michelauz C, Montecucco F, Liberale L, Carbone F. The fat-heart entanglement and the role of "osteopontin mechanics" in cardiometabolic senescence. European Journal of Clinical Investigation. (2026) 56: e70181. doi:. PMID: doi:10.1111/eci.70181
  101. 101 Ma XM, Geng K, Law BY-K, Wang P, Pu YL, Chen Q. Lipotoxicity-induced mtDNA release promotes diabetic cardiomyopathy by activating the cGAS-STING pathway in obesity-related diabetes. Cell Biology and Toxicology. (2023) 39: 277–99. doi: doi:10.1007/s10565-021-09692-z
  102. 102 Karmazyn M, Gan XT. Beyond leptin and adiponectin: the diverse roles of adipokines in the myocardial hypertrophic process and heart failure and their potential contribution in obesity. International Journal of Molecular Sciences. (2025) 27: 3. doi: doi:10.3390/ijms27010003
  103. 103 Dhandapany PS, Kang S, Kashyap DK, Rajagopal R, Sundaresan NR, Singh R. Adiponectin receptor 1 variants contribute to hypertrophic cardiomyopathy that can be reversed by rapamycin. Science Advances. (2021) 7: eabb3991. doi: doi:10.1126/sciadv.abb3991
  104. 104 Karmazyn M, Purdham DM, Rajapurohitam V, Zeidan A. Signalling mechanisms underlying the metabolic and other effects of adipokines on the heart. Cardiovascular Research. (2008) 79: 279–286. doi:. PMID: doi:10.1093/cvr/cvn115
  105. 105 Zhao X, Zhang D, Zhu B, Yao Y, Geng L, Ma X. Chinese visceral adiposity index predicts all-cause mortality in patients with type 2 diabetes, heart failure, and chronic kidney disease: a retrospective cohort study. BMC Research Notes. (2025) 18: 458. doi: doi:10.1186/s13104-025-07531-6
  106. 106 Birkeland KI, Bodegard J, Eriksson JW, Norhammar A, Haller H, Linssen GCM. Heart failure and chronic kidney disease manifestation and mortality risk associations in type 2 diabetes: a large multinational cohort study. Diabetes, Obesity and Metabolism. (2020) 22: 1607–1618. doi:. PMID: doi:10.1111/dom.14074
  107. 107 Rangaswami J, Bhalla V, Blair JEA, Chang TI, Costa S, Lentine KL. Cardiorenal syndrome: classification, pathophysiology, diagnosis, and treatment strategies: a scientific statement from the American Heart Association. Circulation. (2019) 139: e840–e878. doi:. PMID: doi:10.1161/CIR.0000000000000664
  108. 108 Kim M, New E, Lim A, Lim J, Wee JY, Viswambaram A. Cardio-renal-metabolic modeling in Asia-Pacific: projections of clinical and economic burden and empagliflozin's impact on burden reduction. Journal of Medical Economics. (2025) 28: 2103–2118. doi: doi:10.1080/13696998.2025.2590401
  109. 109 Cheng CI, Chou MH, Shih IL, Chen PH, Kao YH. Empagliflozin mitigates high glucose-disrupted mitochondrial respiratory function in H9c2 cardiomyoblasts: a comparative study with NHE-1 and ROCK inhibition. Current Molecular Pharmacology. (2024) 17: e18761429360640. doi: doi:10.2174/0118761429360640250227054103
  110. 110 Lin K, Wang A, Zhai C, Zhao Y, Hu H, Huang D. Semaglutide protects against diabetes-associated cardiac inflammation via Sirt3-dependent RKIP pathway. British Journal of Pharmacology. (2025) 182: 1561–1581. doi: doi:10.1111/bph.17327
  111. 111 Zhang X, Cao C, Zheng F, Liu C, Tian X. Therapeutic potential of GLP-1 receptor agonists in diabetes and cardiovascular disease: mechanisms and clinical implications. Cardiovascular Drugs and Therapy. (2026) 40: 287–301. doi: doi:10.1007/s10557-025-07670-9
  112. 112 Dutta D, Mahajan K, Kamrul-Hasan ABM, Mahajan N, Sharma M, Vohra S. Impact of glucagon-like peptide-1 receptor agonism-based therapies on limb outcomes in peripheral artery disease and type 2 diabetes: an updated systematic review and meta-analysis. Diabetes, Obesity and Metabolism. (2026) 28: 2075–2084. doi: doi:10.1111/dom.70391
  113. 113 Marx N, Deanfield JE, Mann JFE, Arechavaleta R, Bain SC, Bajaj HS. Oral semaglutide and cardiovascular outcomes in people with type 2 diabetes, according to SGLT2i use: prespecified analyses of the SOUL randomized trial. Circulation. (2025) 151: 1639–1650. doi: doi:10.1161/CIRCULATIONAHA.125.074545
  114. 114 Kamrul-Hasan ABM, Chatterjee S, Ashraf H, Nagendra L, Dutta D, Pappachan JM. Cardiovascular outcomes in adults with type 2 diabetes treated with tirzepatide: a systematic review and meta-analysis of real-world studies. Endocrine Practice. (2025) 32: S1530–891X(25)01292-3. doi: doi:10.1016/j.eprac.2025.11.010
  115. 115 Shokravi A, Seth J, Lu N, Mancini GBJ. Effectiveness of SGLT2 inhibitors, incretin-based therapies, and finerenone on cardiorenal outcomes: a meta-analysis and network meta-analysis. Cardiovascular Diabetology Endocrinology Reports. (2025) 11. doi: doi:10.1186/s40842-025-00248-2
  116. 116 Zhang A, Yu J, Ke J, Yin P, Zhang J, Wang C. SGLT2 inhibitors, GLP-1 receptor agonists, and their combination in diabetic cardiomyopathy: a prospective cohort study. Kardiologia Polska. (2025) 83: 814–822. doi: doi:10.33963/v.phj.106152
  117. 117 American Diabetes Association Professional Practice Committee. Cardiovascular disease and risk management: standards of care in diabetes 2026. Diabetes Care. (2026) 49: S216–S245. doi: doi:10.2337/dc26-S010
  118. 118 Tang YJ, Zhang Z, Yan T, Chen K, Xu GF, Xiong SQ. Irisin attenuates type 1 diabetic cardiomyopathy by anti-ferroptosis via SIRT1-mediated deacetylation of p53. Cardiovascular Diabetology. (2024) 23: 116. doi: doi:10.1186/s12933-024-02183-5
  119. 119 Ye H, Guo J, Wang X, Chen B, Hu L, Liu B. Irisin protects against diabetic cardiomyopathy by suppressing ferroptosis. Drug Development Research. (2025) 86: e70077. doi: doi:10.1002/ddr.70077
  120. 120 Shama AM, El-Bassiouny NA, Bahnacy YE, Werida RH. Impact of alpha lipoic acid as an adjuvant therapy on inflammation and fibrosis in type 2 diabetic patients with ischemic cardiomyopathy: a randomized controlled trial. Journal of Dietary Supplements. (2026) 23: 1–22. doi: doi:10.1080/19390211.2025.2601020
  121. 121 Marino F, Scalise M, Salerno N, Salerno L, Molinaro C, Cappetta D. Diabetes-induced cellular senescence and senescence-associated secretory phenotype impair cardiac regeneration and function independently of age. Diabetes. (2022) 71: 1081–1098. doi: doi:10.2337/db21-0536
  122. 122 Hickson LJ, Langhi Prata LGP, Bobart SA, Evans TK, Giorgadze N, Hashmi SK. Senolytics decrease senescent cells in humans: preliminary report from a clinical trial of dasatinib plus quercetin in individuals with diabetic kidney disease. EBioMedicine. (2019) 47: 446–456. doi: doi:10.1016/j.ebiom.2019.08.069
  123. 123 Ji XM, Du XX, Li JP, Tang GJ, Qian S, Wang W. Fisetin clears senescent cells through the PI3K-Akt-Bcl-2/Bcl-xl pathway to alleviate diabetic aortic aging. Phytotherapy Research. (2025) 39 (6): 2757–75. doi: doi:10.1002/ptr.8507
  124. 124 Liang Y, Fan X, Geng X, Jia Y, Shang W, Sun X. Lipid droplets beyond storage: cellular metabolic modulator in the diabetic heart (Review). International Journal of Molecular Medicine. (2026) 57: 82. doi: doi:10.3892/ijmm.2026.5753
  125. 125 Chen W, Jin T, Xie Y, Zhong C, Gao H, Zhang L. Berberine partially ameliorates cardiolipotoxicity in diabetic cardiomyopathy by modulating SIRT3-mediated lipophagy to remodel lipid droplets homeostasis. British Journal of Pharmacology. (2025) 182: 5038–5056. doi: doi:10.1111/bph.70035
  126. 126 Li C, Li Y, Gai Z. Bile acids and farnesoid X receptor: novel target for the treatment of diabetic cardiomyopathy. Current Protein and Peptide Science. (2019) 20: 976–983. doi: doi:10.2174/1389203720666190726152847
  127. 127 Wu H, Liu G, He Y, Da J, Xie B. Obeticholic acid protects against diabetic cardiomyopathy by activation of FXR/Nrf2 signaling in db/db mice. European Journal of Pharmacology. (2019) 858: 172393. doi: doi:10.1016/j.ejphar.2019.05.022
  128. 128 Liu SY, Huang CC, Yang YY, Huang SF, Lee TY, Li TH. Obeticholic acid treatment ameliorates the cardiac dysfunction in NASH mice. PLoS One. (2022) 17: e0276717. doi: doi:10.1371/journal.pone.0276717

Citation

Ren, H. & Lai, H. (2026). Pathogenesis of diabetic cardiomyopathy and emerging therapeutic strategies: a network-based perspective. Frontiers in Clinical Diabetes and Healthcare, Volume 7. https://doi.org/
Received
Accepted
Published
Volume
7 - 2026

Copyright

Copyright © 2026 Ren and Lai.

License: https://creativecommons.org/licenses/by/4.0/

*Correspondence: Hengli Lai

Article metrics

Views
0
Downloads
0
Citations
0
Shares
0

Related articles

Brief Research ReportBehavioral and psychosocial correlates of fasting blood glucose in a resource-constrained diabetes clinic in the Dominican Republic: an exploratory network analysisAmerigo Rossi, Mónica O. Rossi, Aurelina C. Jiménez, Ali BoolaniOriginal ResearchAcceptability of blinded continuous glucose monitoring for people with serious mental illness and type 2 diabetes: findings from an exploratory mixed-methods studyJennifer V.E. Brown, Ramzi A. Ajjan, Najma Siddiqi, Peter A. CoventryOriginal Research“This is going to be a nice-to-know, not a need-to-know”: absence of concern – a qualitative study of risk perception in early detection of type 1 diabetesEmilia Bjergskov Pedersen, Pernille Bech Flarup, Louise Norman Jespersen, Mette Due-Christensen, Julie Christine Antvorskov, Flemming Pociot, Dan Grabowski